Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma

Journal of Photochemistry and Photobiology B: Biology

Volumn 93, Issue 3, 2008, Pages 140-148

  Dögnitz, Nora ^a   Salomon, Denis ^b   Zellweger, Matthieu ^a   Ballini, Jean Pierre ^a   Gabrecht, Tanja ^a   Lange, Norbert ^a   van den Bergh, Hubert ^a   Wagnières, Georges ^a  

^a EPFL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

5 aminolevulinic acid (ALA); 5 aminolevulinic acid ester (ALA ester); Basal cell carcinoma (BCC); Fluorescence spectroscopy; Photodynamic therapy (PDT); Protoporphyrin IX (PpIX)

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; DECODERM BASISCREME; GLASS FIBER; PROTOPORPHYRIN; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL CARCINOMA; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RESPONSE; EMULSION; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; FLUORESCENCE SPECTROSCOPY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SKIN CARCINOMA; SPECTROFLUOROMETRY; SURGICAL TECHNIQUE; VALIDITY;

ADMINISTRATION, TOPICAL; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; SKIN NEOPLASMS; SPECTROMETRY, FLUORESCENCE; TIME FACTORS;

EID: 56749098129     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2008.07.012     Document Type: Article

References (67)

1. Braathen L.R., Szeimies R.M., Basset-Seguin N., Bissonnette R., Foley P., Pariser D., Roelandts R., Wennberg A.M., and Morton C.A. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International society for photodynamic therapy in dermatology, 2005. J. Am. Acad. Dermatol. 56 (2007) 125-143
2. Calzavara-Pinton P., Venturini M., and Sala R. Photodynamic therapy: update 2006, Part 2: clinical results. J. Eur. Acad. Dermatol. Venereol. 21 (2007) 439-451
3. Calzavara-Pinton P.G., Venturini M., and Sala R. Photodynamic therapy: update 2006, Part 1: photochemistry and photobiology. J. Eur. Acad. Dermatol. Venereol. 21 (2007) 293-302
4. Foley P. Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. J. Dermatol. Treat. 14 Suppl. 3 (2003) 15-22
5. Szeimies R.M., and Karrer S. Towards a more specific therapy: targeting nonmelanoma skin cancer cells. Br. J. Dermatol. 154 Suppl. 1 (2006) 16-21
6. Tschen E.H., Wong D.S., Pariser D.M., Dunlap F.E., Houlihan A., and Ferdon M.B. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow-up. Br. J. Dermatol. 155 (2006) 1262-1269
7. Jeffes E.W. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J. Dermatol. Treat. 13 Suppl. 1 (2002) S19-23
8. Taylor E.L., and Brown S.B. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J. Dermatol. Treat. 13 Suppl. 1 (2002) S3-11
9. Caekelbergh K., Annemans L., Lambert J., and Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br. J. Dermatol. 155 (2006) 784-790
10. Ceilley R.I., and Del Rosso J.Q. Current modalities and new advances in the treatment of basal cell carcinoma. Int. J. Dermatol. 45 (2006) 489-498
11. Fritsch C., Homey B., Stahl W., Lehmann P., Ruzicka T., and Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of delta-aminolevulinic acid methylester. Photochem. Photobiol. 68 (1998) 218-221
12. Russo G.G. Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin. Dermatol. 23 (2005) 581-586
13. Svanberg K., Andersson T., Killander D., Wang I., Stenram U., Andersson-Engels S., Berg R., Johansson J., and Svanberg S. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino-levulinic acid sensitization and laser irradiation. Br. J. Dermatol. 130 (1994) 743-751
14. Wolf P., Rieger E., and Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?. J. Am. Acad. Dermatol. 28 (1993) 17-21
15. Moseley H., Ibbotson S., Woods J., Brancaleon L., Lesar A., Goodman C., and Ferguson J. Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre. Lasers Surg. Med. 38 (2006) 403-416
16. Babilas P., Karrer S., Sidoroff A., Landthaler M., and Szeimies R.M. Photodynamic therapy in dermatology - an update. Photodermatol. Photoimmunol. Photomed. 21 (2005) 142-149
17. Baptista J., Martinez C., Leite L., and Cochito M. Our PDT experience in the treatment of non-melanoma skin cancer over the last 7 years. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 693-697
18. Foley P. Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. Australas. J. Dermatol. 46 Suppl. S8-10 (2005) discussion S23-15
19. Fotinos N., Campo M.A., Popowycz F., Gurny R., and Lange N. 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem. Photobiol. 82 (2006) 994-1015
20. Horn M., Wolf P., Wulf H.C., Warloe T., Fritsch C., Rhodes L.E., Kaufmann R., De Rie M., Legat F.J., Stender I.M., Soler A.M., Wennberg A.M., Wong G.A., and Larko O. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br. J. Dermatol. 149 (2003) 1242-1249
21. Kormeili T., Yamauchi P.S., and Lowe N.J. Topical photodynamic therapy in clinical dermatology. Br. J. Dermatol. 150 (2004) 1061-1069
22. Morton C.A. The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments?. J. Dermatol. Treat. 13 (2002) S25-S29
23. Vinciullo C., Elliott T., Francis D., Gebauer K., Spelman L., Nguyen R., Weightman W., Sheridan A., Reid C., Czarnecki D., and Murrell D. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br. J. Dermatol. 152 (2005) 765-772
24. Zeitouni N.C., Oseroff A.R., and Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol. Immunol. 39 (2003) 1133-1136
25. Kloek J., Akkermans W., and Beijersbergen van Henegouwen G.M. Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin. Photochem. Photobiol. 67 (1998) 150-154
26. Donnelly R.F., McCarron P.A., and Woolfson A.D. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem. Photobiol. 81 (2005) 750-767
27. Casas A., Fukuda H., Di Venosa G., and Batlle A.M. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitization. Br. J. Dermatol. 143 (2000) 564-572
28. De Rosa F.S., Marchetti J.M., Thomazini J.A., Tedesco A.C., and Bentley M.V. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J. Control Release 65 (2000) 359-366
29. Malik Z., Kostenich G., Roitman L., Ehrenberg B., and Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of mice. J. Photochem. Photobiol. B 28 (1995) 213-218
30. Peng Q., Warloe T., Moan J., Heyerdahl H., Steen H.B., Nesland J.M., and Giercksky K.E. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem. Photobiol. 62 (1995) 906-913
31. van den Akker J.T., Iani V., Star W.M., Sterenborg H.J., and Moan J. Systemic component of protoporphyrin IX production in nude mouse skin upon topical application of aminolevulinic acid depends on the application conditions. Photochem. Photobiol. 75 (2002) 172-177
32. Ibbotson S. How we treat a superficial basal cell carcinoma with topical photodynamic therapy in Dundee. Photodiag. Photodyn. Ther. 3 (2006) 128-131
33. Wang I., Bendsoe N., Klinteberg C.A., Enejder A.M., Andersson-Engels S., Svanberg S., and Svanberg K. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br. J. Dermatol. 144 (2001) 832-840
34. Jichlinski P., Guillou L., Karlsen S.J., Malmstrom P.U., Jocham D., Brennhovd B., Johansson E., Gartner T., Lange N., van den Bergh H., and Leisinger H.J. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J. Urol. 170 (2003) 226-229
35. Lange N., Jichlinski P., Zellweger M., Forrer M., Marti A., Guillou L., Kucera P., Wagnieres G., and van den Bergh H. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexyl-ester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 80 (1999) 185-193
36. De Rosa F.S., Tedesco A.C., Lopez R.F., Pierre M.B., Lange N., Marchetti J.M., Rotta J.C., and Bentley M.V. In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy. J. Control Release 89 (2003) 261-269
37. Perotti C., Fukuda H., DiVenosa G., MacRobert A.J., Batlle A., and Casas A. Porphyrin synthesis from ALA derivatives for photodynamic therapy. In vitro and in vivo studies. Br. J. Cancer 90 (2004) 1660-1665
38. Casas A., Perotti C., Fukuda H., Rogers L., Butler A.R., and Batlle A. ALA and ALA hexyl-ester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization. Br. J. Cancer 85 (2001) 1794-1800
39. Juzeniene A., Juzenas P., Iani V., and Moan J. Topical application of 5-aminolevulinic acid and its methylester, hexyl-ester and octylester derivatives: considerations for dosimetry in mouse skin model. Photochem. Photobiol. 76 (2002) 329-334
40. Döring F., Walter J., Will J., Föcking M., Boll M., Amasheh S., Clauss W., and Daniel H. Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its physiological and clinical implications. J. Clin. Invest. 101 (1998) 2761-2767
41. Whitaker C.J., Battah S.H., Forsyth M.J., Edwards C., Boyle R.W., and Matthews E.K. Photosensitization of pancreatic tumor cells by ? - aminolaevulinic acid esters. Anti-Cancer Drug Design 15 (2000) 161-170
42. Neumann J., and Brandsch M. 5-aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct. J. Pharmacol. Exp. Ther. 305 (2003) 219-224
43. Rodriguez L., Batlle A., Di Venosa G., Battah S., Dobbin P., MacRobert A.J., and Casas A. Mechanisms of 5-aminolevulic acid ester uptake in mammalian cells. Br. J. Pharmacol. 147 (2006) 825-833
44. Gederaas O.A., Holroyd A., Brown S.B., Vernon D., Moan J., and Berg K. 5-Aminolaevulinic acid methyl-ester transport on amino acid carriers in a human colon adenocarcinoma cell line. Photochem. Photobiol. 73 (2001) 164-169
45. Lange N., Vaucher L., Marti A., Etter A.L., Gerber P., Van Den Bergh H., Jichlinski P., and Kucera P. Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia. J. Biomed. Opt. 6 (2001) 151-159
46. Lopez R.F., Lange N., Guy R., and Bentley M.V. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv. Drug Deliv. Rev. 56 (2004) 77-94
47. Braichotte D.R., Wagnieres G.A., Bays R., Monnier P., and van den Bergh H.E. Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi. Cancer 75 (1995) 2768-2778
48. Baert L., Berg R., Van Damme B., D'Hallewin M.A., Johansson J., Svanberg K., and Svanberg S. Clinical fluorescence diagnosis of human bladder carcinoma following low-dose photofrin injection. Urology 41 (1993) 322-330
49. Weisman R.A., and Silverman D.G. Fiberoptic fluorometer for skin flap assessment. Otolaryngology - Head and Neck Surgery 91 (1983) 377-379
50. de Bruijn H.S., Meijers C., van der Ploeg-van den Heuvel A., Sterenborg H.J.C.M., and Robinson D.J. Microscopic localisation of protoporphyrin IX in normal mouse skin after topical application of 5-aminolevulinic acid or methyl 5-aminolevulinate. J. Photochem. Photobiol. B: Biology 92 (2008) 91-97
51. Ahmadi S., McCarron P.A., Donnelly R.F., Woolfson A.D., and McKenna K. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. Exp. Dermatol. 13 (2004) 445-451
52. Peng Q., Soler A.M., Warloe T., Nesland J.M., and Giercksky K.E. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J. Photochem. Photobiol. B 62 (2001) 140-145
53. Marti A., Jichlinski P., Lange N., Ballini J.P., Guillou L., Leisinger H.J., and Kucera P. Comparison of aminolevulinic acid and hexyl-ester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J. Urol. 170 (2003) 428-432
54. Rebeiz N., Arkins S., Rebeiz C.A., Simon J., Zachary J.F., and Kelley K.W. Induction of tumor necrosis by delta-aminolevulinic acid and 1, 10-phenanthroline photodynamic therapy. Cancer Res. 56 (1996) 339-344
55. Rebeiz N., Rebeiz C.C., Arkins S., Kelley K.W., and Rebeiz C.A. Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: enhancement by 1, 10-phenanthroline. Photochem. Photobiol. 55 (1992) 431-435
56. Rhodes L.E., Tsoukas M.M., Anderson R.R., and Kollias N. Iontophoretic delivery of ALA provides a quantitative model for ALA pharmacokinetics and PpIX phototoxicity in human skin. J. Invest. Dermatol. 108 (1997) 87-91
57. Berger Y., Greppi A., Siri O., Neier R., and Juillerat-Jeanneret L. Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells. J. Med. Chem. 43 (2000) 4738-4746
58. Casas A., Batlle A.M., Butler A.R., Robertson D., Brown E.H., MacRobert A., and Riley P.A. Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures. Br. J. Cancer 80 (1999) 1525-1532
59. Eleouet S., Rousset N., Carre J., Bourre L., Vonarx V., Lajat Y., Beijersbergen van Henegouwen G.M., and Patrice T. In vitro fluorescence toxicity and phototoxicity induced by delta-aminolevulinic acid (ALA) or ALA-esters. Photochem. Photobiol. 71 (2000) 447-454
60. Gerscher S., Connelly J.P., Griffiths J., Brown S.B., MacRobert A.J., Wong G., and Rhodes L.E. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem. Photobiol. 72 (2000) 569-574
61. Kloek J., and Beijersbergen van H. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem. Photobiol. 64 (1996) 994-1000
62. Uehlinger P., Zellweger M., Wagnieres G., Juillerat-Jeanneret L., van den Bergh H., and Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B 54 (2000) 72-80
63. van den Akker J.T., Iani V., Star W.M., Sterenborg H.J., and Moan J. Topical application of 5-aminolevulinic acid hexyl-ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem. Photobiol. 72 (2000) 681-689
64. Yung A., Stables G.I., Fernandez C., Williams J., Bojar R.A., and Goulden V. Microbiological effect of photodynamic therapy (PDT) in healthy volunteers: a comparative study using methyl aminolaevulinate and hexyl aminolaevulinate cream. Clin. Exp. Dermatol. 32 (2007) 716-721
65. G. Wagnières, Overview of the clinical applications of 5-ALA and its derivatives, Abstracts of the 10th World Congress of the International Photodynamic Association, Springer, Berlin, 2005.
66. Eléouet R.N., Carré S., Vonarx J., Vilatte V., Louët C., Lajat C., and Patrice T Y. Heterogeneity of delta-aminolevulinic acid-induced protoporphyrin IX fluorescence in human glioma cells and leukemic lymphocytes. Neurol. Res. 22 (2000) 361-368
67. Uehlinger P., Ballini J.P., van den Bergh H., and Wagnieres G. On the role of iron and one of its chelating agents in the production of protoporphyrin IX generated by 5-aminolevulinic acid and its hexyl-ester derivative tested on an epidermal equivalent of human skin. Photochem. Photobiol. 82 (2006) 1069-1076